Acolbifene
Acolbifene (INN) (developmental code names EM-652, SCH-57068) is a nonsteroidal selective estrogen receptor modulator (SERM) which, as of 2015, is in phase III clinical trials for the treatment of breast cancer.[1][2]
![]() | |
| Clinical data | |
|---|---|
| Other names | EM-652; SCH-57068 |
| Drug class | Selective estrogen receptor modulator |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C29H31NO4 |
| Molar mass | 457.570 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
References
- Gauthier, S; Cloutier, J; Dory, YL; Favre, A; Mailhot, J; Ouellet, C; Schwerdtfeger, A; Mérand, Y; Martel, C; Simard, J; Labrie, F (2005). "Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution". Journal of enzyme inhibition and medicinal chemistry. 20 (2): 165–77. doi:10.1080/14756360500043448. PMID 15968821.
- http://adisinsight.springer.com/drugs/800013630
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.
